Merck's stock surged 73% over the past year, driven by a successful mRNA cancer vaccine trial with Moderna and FDA approval of new drugs like LIPFENDRA, an oral cholesterol treatment. The company has addressed concerns over the upcoming KEYTRUDA patent expiration by building a robust pipeline with over $70 billion in commercial potential from more than 20 new products. Despite the stock's rise, Merck trades at a relatively low 16x forward earnings, suggesting it remains undervalued compared to peers. The key challenge ahead is executing the commercial strategy to capitalize on these innovations and sustain growth.
The Schwab U.S. Dividend Equity ETF (SCHD) has defied bearish macroeconomic conditions by delivering strong returns, largely due to its top holdings such as Abbott Laboratories (ABT), Merck (MRK), and Amgen (AMGN) which posted significant gains after...
Moderna and BioNTech stocks experienced sharp volatility for a third day following a Phase 3 melanoma trial success involving Moderna's mRNA vaccine combined with Merck's Keytruda. Despite no new clinical data Friday, Moderna's shares surged 8%, cont...
The iShares Genomics Immunology and Healthcare ETF (IDNA) surged 13.53% in one day, driven by positive Phase 3 trial results from Moderna and Merck. This jump came with 2.8 times average trading volume, reflecting strong investor interest. IDNA trade...
The Schwab U.S. Dividend Equity ETF (SCHD) has outperformed the S&P 500 in 2026, returning 27.92% through August compared to the S&P 500's 13.85%. This strong performance is due to SCHD's focus on dividend-paying sectors like semiconductors, healthca...
Morgan Stanley upgraded Merck to Overweight with a $179 price target, citing a 17.6% upside following successful Phase 3 results of Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda. The vaccine showed significant improvemen...
